Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn effective ways to earn money online. Explore options that suit your skills and interests for quick cash.
12,726 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
World Liberty Financial, linked to the Trump family, launches a defamation lawsuit against a billionaire after a prev...
A veteran portfolio manager recounts selling a 19-bagger too early and explains how that misstep reshaped his long-te...
Investors often ask where XRP will be in three years. This article examines bear, base, and bull scenarios, plus prac...
When mortgage markets swung on interest-rate headlines, one fund pressed deeper into PennyMac. This article explains ...
When markets hit new highs, Berkshire Hathaway's leaders offer a different playbook. Learn how Warren Buffett's Greg ...
A standout quarterly report helped Rhythm Pharmaceuticals stock surge on Tuesday as investors embraced better-than-ex...
XRP trades around $1.40 with a market cap near $87B. Reaching $20 would require a multi-trillion dollar shift in dema...
XRP sits around $1.40 as institutions quietly expand tokenized-asset settlements on public rails, even as on-chain ac...
Bitcoin steadies as US-Iran tensions ripple through oil and inflation bets. Analysts say these forces could push BTC ...
XRP is testing a breakout near $1.50 as institutional inflows and rising derivatives support a bullish setup. But a m...
The april jobs report reading arrived with mixed signals, while inflation stayed stubborn. Together, they could push ...